Who pushed for those requirements?
And, again, Abbott created the problem. Abbott acted slowly to address the problem. Abbott decides how much product to hold in storage. Abbott pushes for requirements that keep foreign competition low. Though slightly onerous, foreign suppliers could chose to do business in the US. It is not in the link you provided for the FDA to monitor domestic stocks and unilaterally contact foreign suppliers and start importing product.
Stop making me go all TJ/Joe
Abbott takes a loins share of the blame.
There wasn’t competition in the market from Europe because of the FDA’s stupid labeling rules…even though European formula meets standards.
The FDA probably made the labeling rules as to help domestic producers. The FDA has a revolving door with those domestic producers and a serious conflict of interest…got to keep those sweetheart private sector jobs available.
www.science.org
The Food and Drug Administration (FDA) says its rules, along with federal laws, stop employees from improperly cashing in on their government service. But how adequate are those revolving door controls?
Science has found that much like
outside advisers, regular employees at the agency, headquartered in Silver Spring, Maryland, often reap later rewards—jobs or consulting work—from the makers of the drugs they previously regulated.
FDA staffers play a pivotal role in drug approvals, presenting evidence to the agency's advisory panels and influencing or making approval decisions. They are free to move to jobs in pharma, and many do; in a 2016 study in
The BMJ, researchers examined the job histories of 55 FDA staff who had conducted drug reviews over a 9-year period in the hematologyoncology field. They found that 15 of the 26 employees who left the agency later worked or consulted for the biopharmaceutical industry.
FDA's safeguards are supposed to keep the prospect of industry employment from affecting employees' decisions while at the agency, and to discourage them from exploiting relationships with former colleagues after they depart. For example, former high-level employees can't appear before the agency on the precise issues they regulated—sometimes permanently, in other cases for a year or two.